com_NN Shareholder_NN information_NN AstraZeneca_NNP 2000 2001 2002 2003_CD 2004_CD Ordinary_NNP Shares_NNP in_IN issue_NN millions_NNS At_IN year_NN end_NN 1,766_CD 1,745_CD 1,719_CD 1,693_CD 1,645_CD Weighted_VBN average_NN for_IN year_NN 1,768_CD 1,758_CD 1,733_CD 1,709_CD 1,673_CD Stock_NN market_NN price_NN per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP Highest_NNP pence_NN 3600 3555 3625 2868_CD 2749_CD Lowest_NNP pence_NN 1926 2880 1799 1820_CD 1863_CD At_IN year_NN end_NN pence_NN 3375 3098 2220 2680_CD 1889_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS $_$ 1.62_CD $_$ 1.73_CD $_$ 1.84_CD $_$ 1.78_CD $_$ 2.11_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP basic_JJ $_$ 1.30_CD $_$ 1.65_CD $_$ 1.64_CD $_$ 1.78_CD $_$ 2.28_CD Earnings_NNS per_IN $_$ 0.25_CD Ordinary_NNP Share_NNP diluted_VBD $_$ 1.30_CD $_$ 1.65_CD $_$ 1.64_CD $_$ 1.78_CD $_$ 2.28_CD Dividends_NNPS $_$ 0.70_CD $_$ 0.70_CD $_$ 0.70_CD $_$ 0.795_CD $_$ 0.94_CD In_IN addition_NN ,_, shareholders_NNS received_VBD a_DT distribution_NN of_IN shares_NNS in_IN Syngenta_NNP AG_NNP as_IN a_DT dividend_NN in_IN specie_NN in_IN respect_NN of_IN the_DT demerger_NN of_IN Zeneca_NNP Agrochemicals_NNPS ._.
Percentage_NN analysis_NN at_IN 31_CD December_NNP 2004_CD of_IN issued_VBN share_NN capital_NN By_IN size_NN of_IN account_NN 2004_CD No._NN ._.
In_IN addition_NN ,_, there_EX were_VBD approximately_RB 45,000_CD holders_NNS of_IN American_JJ Depositary_NNP Receipts_NNPS ADRs_NNPS representing_VBG 8.82_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN and_CC 161,000_CD holders_NNS of_IN shares_NNS held_VBN under_IN the_DT VPC_NNP Services_NNPS Agreement_NNP representing_VBG 22.63_CD %_NN of_IN the_DT issued_VBN share_NN capital_NN ._.
The_DT ADRs_NNPS ,_, each_DT of_IN which_WDT is_VBZ equivalent_JJ to_TO one_CD Ordinary_NNP Share_NN ,_, are_VBP issued_VBN by_IN JPMorgan_NNP Chase_NNP Bank_NNP ._.
Financial_NNP calendar_NN 2005_CD 28_CD April_NNP 2005_CD Annual_JJ General_NNP Meeting_VBG and_CC announcement_NN of_IN first_JJ quarter_NN 2005_CD results_NNS 28_CD July_NNP 2005_CD Announcement_NN of_IN second_JJ quarter_NN and_CC first_JJ half_NN 2005_CD results_NNS 27_CD October_NNP 2005_CD Announcement_NN of_IN third_JJ quarter_NN and_CC nine_CD months_NNS 2005_CD results_NNS Dividend_NN payments_NNS The_DT record_NN date_NN for_IN the_DT second_JJ interim_JJ dividend_NN for_IN 2004_CD ,_, payable_JJ on_IN 21_CD March_NNP 2005_CD in_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP ,_, is_VBZ 11_CD February_NNP 2005_CD ._.
Shares_NNP trade_NN ex-dividend_NN on_IN the_DT London_NNP and_CC Stockholm_NNP Stock_NNP Exchanges_NNPS from_IN 9_CD February_NNP 2005_CD and_CC ADRs_NNPS trade_NN ex-dividend_NN on_IN the_DT New_NNP York_NNP Stock_NNP Exchange_NNP from_IN the_DT same_JJ date_NN ._.
From_IN 2005_CD ,_, dividends_NNS will_MD normally_RB be_VB paid_VBN as_IN follows_VBZ :_: First_NNP interim_JJ :_: Announced_JJ end_NN of_IN July_NNP and_CC paid_VBN in_IN September_NNP ._.
Second_JJ interim_NN :_: Announced_JJ end_NN of_IN January_NNP and_CC paid_VBN in_IN March_NNP ._.
The_DT record_NN date_NN for_IN the_DT first_JJ interim_JJ dividend_NN for_IN 2005_CD ,_, payable_JJ on_IN 19_CD September_NNP 2005_CD in_IN the_DT UK_NNP ,_, the_DT US_NNP and_CC Sweden_NNP ,_, is_VBZ 12_CD August_NNP 2005_CD ._.
2004_CD dividend_NN $_$ pence_NN SEK_NNP Payment_NN date_NN First_NNP interim_JJ dividend_NN 0.295_CD 16.0_CD 2.200_CD 20_CD September_NNP 2004_CD Second_JJ interim_JJ dividend_NN 0.645_CD 34.3_CD 4.497_CD 21_CD March_NNP 2005_CD Total_JJ dividend_NN 0.940_CD 50.3_CD 6.697_CD Annual_JJ Review_NNP 2004_CD 36_CD astrazeneca_NN ._.
com_NN The_DT contents_NNS of_IN this_DT AstraZeneca_NNP Annual_JJ Shareview_NNP Statements_NNP of_IN competitive_JJ position_NN AstraZenecas_NNP shareholders_NNS with_IN internet_NN Review_NNP are_VBP derived_VBN wholly_RB and_CC exclusively_RB Except_IN as_IN otherwise_RB stated_VBN ,_, market_NN information_NN access_NN may_MD visit_VB shareview_NN ._.
co._JJ uk_NN and_CC register_NN from_IN the_DT AstraZeneca_NNP Annual_JJ Report_NNP and_CC in_IN this_DT Annual_JJ Review_NNP 2004_CD regarding_VBG the_DT their_PRP$ details_NNS to_TO create_VB a_DT portfolio_NN ._.
Shareview_NNP is_VBZ a_DT Form_NN 20-F_JJ Information_NN for_IN the_DT financial_JJ year_NN position_NN of_IN our_PRP$ business_NN or_CC products_NNS relative_JJ free_JJ and_CC secure_JJ on-line_JJ service_NN from_IN Lloyds_NNP TSB_NNP ended_VBD 31_CD December_NNP 2004_CD ,_, to_TO which_WDT the_DT reader_NN to_TO its_PRP$ or_CC their_PRP$ competition_NN is_VBZ based_VBN upon_IN Registrars_NNPS that_WDT gives_VBZ access_NN to_TO shareholdings_NNS is_VBZ referred_VBN for_IN additional_JJ analytical_JJ information_NN ._.
published_VBN statistical_JJ data_NNS for_IN the_DT 12_CD months_NNS including_VBG balance_NN movements_NNS ,_, indicative_JJ share_NN ended_VBN 30_CD September_NNP 2004_CD ,_, obtained_VBN from_IN IMS_NNP prices_NNS and_CC information_NN about_IN recent_JJ dividends_NNS ._.
Trade_NNP marks_VBZ Health_NNP ,_, a_DT leading_VBG supplier_NN of_IN statistical_JJ data_NNS to_TO Trade_NNP marks_NNS of_IN the_DT AstraZeneca_NNP group_NN of_IN the_DT pharmaceutical_JJ industry_NN ._.
Except_IN as_IN ShareGift_NNP companies_NNS appear_VBP throughout_IN this_DT document_NN in_IN otherwise_RB stated_VBN ,_, these_DT market_NN share_NN and_CC AstraZeneca_NNP welcomes_VBZ and_CC values_VBZ all_DT its_PRP$ italics_NNS ._.
AstraZeneca_NNP ,_, the_DT AstraZeneca_NNP logotype_NN industry_NN data_NNS from_IN IMS_NNP Health_NNP have_VBP been_VBN shareholders_NNS ,_, no_DT matter_NN how_WRB many_JJ or_CC how_WRB few_JJ and_CC the_DT AstraZeneca_NNP symbol_NN are_VBP all_DT trade_NN marks_NNS derived_VBN by_IN comparing_VBG our_PRP$ sales_NNS revenue_NN to_TO shares_NNS they_PRP own_VBP ._.
However_RB ,_, shareholders_NNS who_WP of_IN the_DT AstraZeneca_NNP group_NN of_IN companies_NNS ._.
competitors_NNS and_CC total_JJ market_NN sales_NNS revenues_NNS have_VBP only_RB a_DT small_JJ number_NN of_IN shares_NNS whose_WP$ for_IN that_DT period_NN ._.
value_NN makes_VBZ it_PRP uneconomic_JJ to_TO sell_VB them_PRP ,_, either_DT Use_NN of_IN terms_NNS now_RB or_CC at_IN some_DT stage_NN in_IN the_DT future_NN ,_, may_MD wish_VB In_IN this_DT Annual_JJ Review_NNP 2004_CD ,_, unless_IN the_DT context_NN Statements_NNS of_IN growth_NN rates_NNS to_TO consider_VB donating_VBG them_PRP to_TO charity_NN through_IN otherwise_RB requires_VBZ ,_, AstraZeneca_NNP ,_, the_DT Group_NNP ,_, Except_IN as_IN otherwise_RB stated_VBN ,_, growth_NN rates_NNS in_IN this_DT ShareGift_NNP ,_, an_DT independent_JJ charity_NN share_NN the_DT Company_NN ,_, we_PRP ,_, us_PRP and_CC our_PRP$ refer_VBP to_TO Annual_JJ Review_NNP 2004_CD are_VBP given_VBN at_IN constant_JJ donation_NN scheme_NN ._.
One_CD feature_NN of_IN the_DT scheme_NN is_VBZ AstraZeneca_NNP PLC_NNP and_CC its_PRP$ consolidated_JJ entities_NNS ._.
that_IN there_EX is_VBZ no_DT gain_NN or_CC loss_NN for_IN capital_NN gains_NNS tax_NN purposes_NNS on_IN gifts_NNS of_IN shares_NNS through_IN ShareGift_NNP Cautionary_NNP statement_NN regarding_VBG AstraZeneca_NNP websites_NNS and_CC it_PRP may_MD now_RB also_RB be_VB possible_JJ to_TO obtain_VB forward-looking_JJ statements_NNS Information_NN on_IN our_PRP$ websites_NNS ,_, including_VBG income_NN tax_NN relief_NN on_IN the_DT donation_NN ._.
Further_JJ In_IN order_NN to_TO utilise_VB the_DT safe_JJ harbor_NN provisions_NNS of_IN astrazeneca_NN ._.
com_NN and_CC information_NN about_IN ShareGift_NNP can_MD be_VB found_VBN the_DT US_NNP Private_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP ._.
com_NN does_VBZ not_RB on_IN its_PRP$ website_NN ,_, sharegift_NN ._.
org_NN ,_, or_CC by_IN contacting_VBG 1995_CD ,_, we_PRP are_VBP providing_VBG the_DT following_VBG cautionary_JJ form_NN part_NN of_IN this_DT document_NN ._.
ShareGift_NNP on_IN 020 7337 0501_CD or_CC at_IN 46_CD Grosvenor_NNP statement_NN :_: This_DT Annual_JJ Review_NNP 2004_CD contains_VBZ Street_NNP ,_, London_NNP W1K_NNP 3HN_NNP ._.
More_JJR information_NN certain_JJ forward-looking_JJ statements_NNS about_IN about_IN the_DT tax_NN position_NN on_IN gifts_NNS of_IN shares_NNS to_TO AstraZeneca_NNP ._.
Although_IN we_PRP believe_VBP our_PRP$ ShareGift_NNP can_MD be_VB obtained_VBN from_IN the_DT Inland_NNP expectations_NNS are_VBP based_VBN on_IN reasonable_JJ Revenue_NN whose_WP$ website_JJ address_NN is_VBZ assumptions_NNS ,_, any_DT forward-looking_JJ statements_NNS inlandrevenue_NN ._.
The_DT share_NN transfer_NN form_NN may_MD be_VB influenced_VBN by_IN factors_NNS that_WDT could_MD cause_VB needed_VBN to_TO make_VB a_DT donation_NN may_MD be_VB obtained_VBN actual_JJ outcomes_NNS and_CC results_NNS to_TO be_VB materially_RB from_IN the_DT AstraZeneca_NNP Registrar_NNP ,_, Lloyds_NNP TSB_NNP different_JJ from_IN those_DT predicted_VBN ._.
We_PRP identify_VBP the_DT Registrars_NNPS whose_WP$ address_NN can_MD be_VB found_VBN on_IN the_DT forward-looking_JJ statements_NNS by_IN using_VBG the_DT words_NNS back_RB cover_VBP of_IN this_DT document_NN ._.
ShareGift_NNP is_VBZ anticipates_VBZ ,_, believes_VBZ ,_, expects_VBZ ,_, intends_VBZ and_CC AstraZeneca_NNP PLC_NNP 2005_CD administered_VBN by_IN The_DT Orr_NNP Mackintosh_NNP similar_JJ expressions_NNS in_IN such_JJ statements_NNS ._.
These_DT Foundation_NNP ,_, registered_VBD charity_NN number_NN forward-looking_JJ statements_NNS are_VBP subject_JJ to_TO 1052686_CD ._.
numerous_JJ risks_NNS and_CC uncertainties_NNS ._.
Important_JJ factors_NNS that_WDT could_MD cause_VB actual_JJ results_NNS to_TO differ_VB The_DT Unclaimed_NNP Assets_NNPS Register_NNP materially_RB from_IN those_DT contained_VBN in_IN forwardAstraZeneca_NNP supplies_NNS unclaimed_JJ dividend_NN data_NNS looking_VBG statements_NNS ,_, certain_JJ of_IN which_WDT are_VBP beyond_IN to_TO the_DT Unclaimed_NNP Assets_NNPS Register_NNP UAR_NNP which_WDT our_PRP$ control_NN ,_, include_VBP ,_, among_IN other_JJ things_NNS :_: the_DT provides_VBZ investors_NNS who_WP have_VBP lost_VBN track_NN of_IN loss_NN or_CC expiration_NN of_IN patents_NNS ,_, marketing_NN shareholdings_NNS with_IN an_DT opportunity_NN to_TO search_VB exclusivity_NN or_CC trade_NN marks_NNS :_: exchange_NN rate_NN the_DT UARs_NNPS database_NN of_IN unclaimed_JJ financial_JJ fluctuations_NNS :_: the_DT risk_NN that_IN R&D_NNP will_MD not_RB yield_VB new_JJ assets_NNS on_IN payment_NN of_IN a_DT small_JJ ,_, fixed_JJ fee_NN ._.
The_DT products_NNS that_WDT achieve_VBP commercial_JJ success_NN :_: the_DT UAR_NNP donates_VBZ part_NN of_IN the_DT search_NN fee_NN to_TO charity_NN ._.
impact_NN of_IN competition_NN ,_, price_NN controls_NNS and_CC price_NN The_DT UAR_NNP can_MD be_VB contacted_VBN at_IN Leconfield_NNP reductions_NNS :_: taxation_NN risks_NNS :_: the_DT risk_NN of_IN substantial_JJ House_NNP ,_, Curzon_NNP Street_NNP ,_, London_NNP W1J_NNP 5JA_NNP product_NN liability_NN claims_NNS :_: the_DT impact_NN of_IN any_DT failure_NN and_CC at_IN uar_NN ._.
by_IN third_JJ parties_NNS to_TO supply_VB materials_NNS or_CC services_NNS :_: the_DT risk_NN of_IN delay_NN to_TO new_JJ product_NN launches_NNS :_: the_DT difficulties_NNS of_IN obtaining_VBG and_CC maintaining_VBG governmental_JJ approvals_NNS for_IN products_NNS :_: and_CC the_DT risk_NN of_IN environmental_JJ liabilities_NNS ._.
Designed_VBN by_IN Addison_NNP Corporate_NNP Marketing_NNP Ltd_NNP
